08:00 , Nov 16, 2015 |  BC Week In Review  |  Clinical News

AV-101 L-4-chlorokynurenine: Phase IIa started

VistaGen said NIH’s National Institute of Mental Health (NIMH) began a double-blind, placebo-controlled, crossover, U.S. Phase IIa trial to evaluate 1,080 and 1,440 mg oral AV-101 once daily for 14 days in 24-28 patients with...
07:00 , Mar 16, 2015 |  BC Week In Review  |  Clinical News

AV-101: Phase II start

Next quarter, VistaGen said NIH’s National Institute of Mental Health (NIMH) will begin a double-blind, placebo-controlled, crossover, U.S. Phase II trial to evaluate 1,440 mg oral AV-101 once daily for 14 days in about 25...
08:00 , Jan 28, 2013 |  BC Week In Review  |  Clinical News

AV-101: Phase I data

A double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial in 46 healthy volunteers showed that once-daily 360, 1,080 and 1,440 mg doses of oral AV-101 for 14 days were well tolerated with "favorable" bioavailability and pharmacokinetics....
07:00 , May 23, 2011 |  BC Week In Review  |  Company News

VistaGen, Excalib deal

VistaGen reverse-merged with shell company Excaliber. VistaGen shareholders own 90% of the combined company and Excaliber owns 10%. The company will receive a new ticker once Excaliber changes its name to VistaGen Therapeutics Inc. VistaGen's...
08:00 , Jan 3, 2011 |  BC Week In Review  |  Clinical News

AV-101: Phase I data

A double-blind, placebo-controlled Phase I trial in healthy volunteers showed that single doses of AV101 were well tolerated with no serious adverse events reported. Data from a second ongoing Phase I safety trial of AV101...
08:00 , Nov 19, 2007 |  BC Week In Review  |  Clinical News

VistaGen preclinical data

In rats, systemic administration of AV-101 increased the firing rate and burst firing activity of dopaminergic neurons by 27% and 61%, respectively. In the brain, AV-101 is converted to 7-chlorokynurenic acid, a selective regulator of...
08:00 , Dec 11, 2006 |  BC Week In Review  |  Clinical News

VistaGen preclinical data

VistaGen said preclinical studies suggest that AV-101 can stimulate the firing of dopaminergic neurons, the neurons that die in PD. VistaGen Therapeutics Inc., Burlingame, Calif.   Product: AV-101   Indication: Treat Parkinson's disease (PD)   ...
08:00 , Nov 24, 2003 |  BC Week In Review  |  Company News

Artemis Neuroscience Inc., VistaGen deal

VistaGen acquired Artemis, which develops therapeutics for epilepsy, neuropathic pain and other CNS disorders. Through the acquisition, VistaGen added to its pipeline Artemis' AV-101, a preclinical compound for epilepsy. VistaGen believes the indirectly acting...